Asset profile
Recombinant human growth hormone
Biologic — subtype unspecified
Evidence outlook · registrational
Chronic Kidney Disease: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.
NCT00244075: The study was randomized and compared an active combination containing recombinant human growth hormone with nutritional supplementation alone, but it was open-label and evaluated the short-term physiological measure of net muscle protein balance rather than a clinical outcome. No primary-endpoint results are posted, so the comparison cannot be judged as met or missed.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.